Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Brewer

Clinical Cardiac Electrophysiology Huntington, WV Medical Doctor

NPI 1790715308 CMS profile 642316

5170 US Rt 60 East, Huntington, WV 25705

Open in the dashboard

General payments

$9,371

265 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Brewer of Huntington, WV is reported in the CMS Open Payments database as having received $9,371 across 265 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $418 44
2024 General $1,985 53
2023 General $742 47
2022 General $620 33
2021 General $231 14
2020 General $304 12
2019 General $5,071 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Brewer
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Robert Brewer were reported at $418. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Robert Brewer Clinical Cardiac Electrophysiology median Middle half National median
2019 $5,071 $2,361 $585–$8,260 $163
2020 $304 $993 $247–$4,351 $114
2021 $231 $1,185 $326–$4,739 $132
2022 $620 $2,073 $554–$6,789 $149
2023 $742 $2,568 $759–$8,159 $160
2024 $1,985 $2,557 $703–$7,403 $164
2025 $418 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,912 132 payments
  2. Medtronic Vascular, Inc. $1,317 14 payments
  3. Medtronic, Inc. $1,195 5 payments
  4. Abbott Laboratories $468 23 payments
  5. Pfizer Inc. $275 16 payments
  6. Novartis Pharmaceuticals Corporation $260 16 payments
  7. Janssen Pharmaceuticals, Inc $235 13 payments
  8. Sanofi-Aventis U.S. LLC $148 7 payments
  9. E.R. Squibb & Sons, L.L.C. $144 13 payments
  10. Amgen Inc. $82 5 payments
  11. Other $335 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,976 252 payments
  2. Travel and Lodging $4,395 13 payments
Products named General payments · program years 2019–2025
  1. RHYTHMIA $3,133 22 payments
  2. PULSESELECT $1,101 3 payments
  3. MICRA $686 7 payments
  4. Reveal LINQ $571 4 payments
  5. ACCOLADE SR $494 69 payments
  6. General Therapies $286 3 payments
  7. ENTRESTO $260 16 payments
  8. XARELTO $235 13 payments
  9. Rhythmia Mapping System $209 4 payments
  10. PAXLOVID $200 11 payments
  11. Other $2,453 136 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,051

Median for Cardiology: 2,533

Drug cost

$218,292

Median for Cardiology: $485,213

Branded share of claims

28.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 189 $154,099
Xarelto Rivaroxaban Brand 39 $30,857
Multaq Dronedarone Hcl Brand 20 $23,536
Flecainide Acetate Generic 116 $2,452
Metoprolol Succinate Generic 269 $2,430
Amiodarone Hcl Generic 183 $1,752
Mexiletine Hcl Generic 23 $1,500
Sotalol Sotalol Hcl Brand 32 $530
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 23 $401
Pantoprazole Sodium Generic 70 $280

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$121,937

Medicare's payments for the services billed

Medicare patients

431

Average age 77

Services billed

942

189 women, 242 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 48%
Heart failure 46%
Chronic kidney disease 42%
Diabetes 40%
Arthritis 40%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record